Clinical trials: Vaccine Immune Response
Meningococcal Disease, Meningococcal Meningitis
A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY
The primary objective is to evaluate the persistence of bactericidal antibodies in adolescent subjects who completed study V59P6 in which they received either Novartis Meningococcal (MenACWY) Conjugate Vaccine or Licensed…
- Trial name
- NCT01018732
- Testing
- Novartis Meningococcal (MenACWY-CRM) vaccine
- Where
- 3 sites in United States
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenic Purpura
Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura
The purpose of this study is to determine how children with a history of severe, chronic Idiopathic Thrombocytopenic Purpura (ITP) who were treated with rituximab might respond to vaccines.
- Trial name
- NCT01713855
- Testing
- Inactivated Trivalent Influenza vaccine
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Neufeld, Ellis J, MD, PhD
HIV Infections
A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART
To ascertain the effect of thalidomide on immune responses to vaccination with polyvalent pneumococcal polysaccharide vaccine and tetanus toxoid in HIV-infected patients; particularly, on markers of immune activation and…
- Trial name
- NCT00002392
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Rockefeller University
Meningococcal Disease
Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)
The purpose of this extension study is to evaluate the immunogenicity and safety of a booster dose of a MenABCWY vaccine, administered 24 months after completion of the primary vaccination series, in subjects who previously…
- Trial name
- NCT01992536
- Testing
- MenABCWY+OMV, MenABCWY+¼OMV
- Where
- 13 sites in United States, Poland
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Hematologic Diseases
Evaluation of the Immune Response to Sars-Covid-19 Vaccines in Haematological Patients: Prospective Single Center Study
The main objective of this study is to investigate the humoral immune response to COVID-19 vaccines in haematological patients, by testing SARS-CoV-2 seroconversion
- Trial name
- Hema-C19-Vax (NCT05074706)
- Testing
- IgG antibodies to Sars-Cov-2, QuantiFERON SARS-CoV-2 test
- Where
- Italy
- Volunteers
- 700 people
- Sponsor
- University of Milano Bicocca
Antibody Persistance After Booster Dose of Men C Vaccine
Understanding Immunity Persistence After Adolescent MenC Vaccination
The main purpose of this study is to evaluate the duration of immunity after a booster dose of a MenC-CRM vaccine given to adolescents between 13 and 15 years of age.
- Trial name
- NCT01459432
- Testing
- Venepuncture and blood sample collection.
- Where
- United Kingdom
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Prevention of Meningococcal Infection
Persistence of Immune Response After Vaccination With MCC
Persistence of Immune response after vaccination with MCC
- Trial name
- NCT00310687
- Testing
- BLOOD DRAW
- Where
- United Kingdom
- Volunteers
- 1,244 people, healthy volunteers welcome
- Sponsor
- Novartis
Immunization
FluPRINT Study: Characterisation of the Immune and Transcriptional Response to LAIV
In 2013 the UK government introduced the nasal flu spray vaccine (Fluenz Tetra®) for use in children from 24 months to less than 18 years of age.
- Trial name
- NCT04222595
- Testing
- Fluenz Tetra nasal spray suspension
- Where
- United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients…
- Conditions
- Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT06784167
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- OHSU Knight Cancer Institute
Acquired Immune Deficiency Syndrome Virus
Exploring Novel Mechanisms of Vaccine Failure LAIV Pilot Study
Influenza ('flu) can cause severe infections, especially in people with weakened immune systems such as those with HIV. For this reason, yearly vaccination is recommended with the standard 'inactivated' influenza vaccine to try…
- Trial name
- LAIV (NCT02266992)
- Testing
- Live attenuated Vaccine- Fluenz Tretra
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Chickenpox
A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age
The purpose of this study is to evaluate the immune response and safety of GSKs investigational varicella vaccine (VNS Vaccine) compared to an already approved varicella vaccine, Varivax (VV), when administered as second dose to…
- Trial name
- NCT06806137
- Testing
- Investigational varicella vaccine, Marketed varicella vaccine, MMR vaccine
- Where
- 6 sites in Dominican Republic, Honduras
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ebola Virus Disease, Marburg Virus Disease
Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults
Primary Objective: To evaluate the safety and tolerability of cAd3-EBO-S and cAd3 Marburg vaccines when administered Intramuscular (IM) at a dose of 1 x 10^11 particle units (PU) to healthy adults.
- Trial name
- NCT04723602
- Testing
- cAd3-Marburg, cAd3-EBO-S
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Influenza, Influenza, Human
Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults
The purpose of this study is to evaluate the body's immune response at different time points to an FDA-approved seasonal influenza vaccine.
- Conditions
- Influenza, Influenza, Human, Vaccine Reaction, Influenza A
- Trial name
- KIRV (NCT03743688)
- Testing
- Influenza Vaccine Recipients
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Rheumatoid Arthritis
The Effect of Rituximab on the Humoral Response to Influenza Vaccine
Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody that selectively targets CD20+ B cells and induces a transient depletion of the CD20+ mature B cell subpopulation.The objective of our study was to…
- Trial name
- NCT00466037
- Testing
- Influenza vaccine
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Pneumococcal Infection
Systems Biology of PNEUMOVAX®23 and PREVNAR 13®
Vaccination is the most effective way of preventing infectious diseases. Despite the success of vaccines in general, vaccines induce diminished antibody responses and lower protection in the elderly in particular.
- Trial name
- NCT01307449
- Testing
- PNEUMOVAX, Prevnar
- Where
- 2 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Emory University
Prevention of Influenza
Study of Biomarkers of Immune Activation Associated with Symptoms and Immune Responses After Influenza Vaccination in Adults
This clinical fase IV study, using the administration of a single dose of a quadrivalent, inactivated, split influenza virus vaccine as biological intervention will mirror a study conducted at Imperial College, London, UK that…
- Trial name
- NCT03160118
- Testing
- Seasonal,quadrivalent,influenza vaccine
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Diphtheria-Tetanus-acellular Pertussis Vaccines
A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 Years
The purpose of the study is to assess the immune response, reactogenicity and safety of a booster dose of dTpa vaccine 1 month after vaccination in healthy Japanese participants aged 11 to <13 years.
- Trial name
- NCT07596173
- Testing
- dTpa vaccine
- Where
- 10 sites in Japan
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Poliomyelitis
An Immunity Persistence Study of Sabin Inactivated Poliovirus Vaccine(Vero Cell) After Four Doses
This is an open and observational follow-up clinical trial based on the previous Phase III clinical trial of Sabin Inactivated Poliovirus Vaccine manufactured by Sinovac Biotech Co.
- Trial name
- NCT04989231
- Testing
- Investigational sIPV, Control IPV
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Sinovac Biotech Co., Ltd
Prevention of COVID-19
Assessing Immune Response of Different COVID-19 Vaccines in Older Adults
This is a randomised controlled, adaptive, multicentre Phase II protocol evaluating different booster strategies in individuals aged 75 years and older already vaccinated against SARS-CoV-2.
- Trial name
- EU-COVAT-1 (NCT05160766)
- Testing
- Comirnaty (BTN162b2), Spikevax (mRNA-1273)
- Where
- 9 sites in Germany, Lithuania and 2 more
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Oliver Cornely, MD
Ebola Sudan Virus Disease
A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
- Trial name
- NCT06803342
- Testing
- cAd3-Sudan Vaccine
- Where
- 4 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute